Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis

被引：11

作者：

Hu, Mingwei ^{[1
]}

Zhang, Yifan ^{[1
]}

Guo, Jianjun ^{[1
]}

Guo, Cuicui ^{[1
]}

Yang, Xue ^{[1
]}

Ma, Xue ^{[1
]}

Xu, Hao ^{[1
]}

Xiang, Shuai ^{[1
]}

机构：

[1] Qingdao Univ, Affiliated Hosp, Dept Joint Surg, Qingdao, Peoples R China

来源：

FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷

关键词：

osteoporosis; denosumab; romosozumab; bone mineral density; bone turnover marker; POSTMENOPAUSAL WOMEN; SCLEROSTIN; WNT; ANTIBODY; OSTEOPROTEGERIN; RESORPTION; LIGAND; RANKL; MASS;

D O I：

10.3389/fendo.2023.1188969

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: To assess the alterations in bone mineral density and bone turnover marker concentrations following the administration of denosumab and romosozumab therapies in patients with osteoporosis.Methods: PubMed was searched for studies published until January 28, 2023, that investigated the clinical efficacy and bone turnover marker changes of denosumab and romosozumab in the treatment of osteoporosis, with a minimum follow-up of 3 months in each study. Studies were screened, and data on changes in bone mineral density (BMD), P1NP, and TRACP-5b levels after treatment were extracted and included in the analysis.Results: Six studies were analyzed. At 3 months after treatment, the romosozumab group showed greater changes in lumbar BMD and bone turnover markers. BMD of total hip and femoral neck was relatively delayed. Beginning at 6 to 12 months, romosozumab showed greater changes in bone mineral density and markers of bone turnover.Conclusion: Both romosozumab and denosumab have antiosteoporotic effects, with greater effects on BMD and bone turnover markers observed within 12 months of romosozumab treatment.

引用

页数：9

共 42 条

[1] Fatigue as the missing link between bone fragility and fracture [J].

Acevedo, Claire ;

Stadelmann, Vincent A. ;

Pioletti, Dominique P. ;

Alliston, Tamara ;

Ritchie, Robert O. .

NATURE BIOMEDICAL ENGINEERING, 2018, 2 (02) :62-71

[2] Minireview:: Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton [J].

Baron, Roland ;

Rawadi, Georges .

ENDOCRINOLOGY, 2007, 148 (06) :2635-2643

[3] 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension [J].

Bone, Henry G. ;

Wagman, Rachel B. ;

Brandi, Maria L. ;

Brown, Jacques P. ;

Chapurlat, Roland ;

Cummings, Steven R. ;

Czerwinski, Edward ;

Fahrleitner-Pammer, Astrid ;

Kendler, David L. ;

Lippuner, Kurt ;

Reginster, Jean-Yves ;

Roux, Christian ;

Malouf, Jorge ;

Bradley, Michelle N. ;

Daizadeh, Nadia S. ;

Wang, Andrea ;

Dakin, Paula ;

Pannacciulli, Nicola ;

Dempster, David W. ;

Papapoulos, Socrates .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) :513-523

[4] Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials [J].

Bouxsein, Mary L. ;

Eastell, Richard ;

Lui, Li-Yung ;

Wu, Lucy A. ;

de Papp, Anne E. ;

Grauer, Andreas ;

Marin, Fernando ;

Cauley, Jane A. ;

Bauer, Douglas C. ;

Black, Dennis M. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (04) :632-642

[5] Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches [J].

Canalis, Ernesto .

NATURE REVIEWS ENDOCRINOLOGY, 2013, 9 (10) :575-583

[6] Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment [J].

Chavassieux, Pascale ;

Chapurlat, Roland ;

Portero-Muzy, Nathalie ;

Roux, Jean-Paul ;

Garcia, Pedro ;

Brown, Jacques P. ;

Libanati, Cesar ;

Boyce, Rogely W. ;

Wang, Andrea ;

Grauer, Andreas .

JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (09) :1597-1608

[7] Safety of long-term denosumab therapy for osteoporosis [J].

Compston, Juliet .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) :485-487

[8] Romosozumab Treatment in Postmenopausal Women with Osteoporosis [J].

Cosman, F. ;

Crittenden, D. B. ;

Adachi, J. D. ;

Binkley, N. ;

Czerwinski, E. ;

Ferrari, S. ;

Hofbauer, L. C. ;

Lau, E. ;

Lewiecki, E. M. ;

Miyauchi, A. ;

Zerbini, C. A. F. ;

Milmont, C. E. ;

Chen, L. ;

Maddox, J. ;

Meisner, P. D. ;

Libanati, C. ;

Grauer, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (16) :1532-1543

[9] Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk [J].

Fixen, Cy ;

Tunoa, Jennifer .

CURRENT OSTEOPOROSIS REPORTS, 2021, 19 (01) :15-22

[10] Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation [J].

Glass, DA ;

Bialek, P ;

Ahn, JD ;

Starbuck, M ;

Patel, MS ;

Clevers, H ;

Taketo, MM ;

Long, FX ;

McMahon, AP ;

Lang, RA ;

Karsenty, G .

DEVELOPMENTAL CELL, 2005, 8 (05) :751-764

← 1 2 3 4 5 →